Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses.

OBJECTIVE To evaluate two hypotheses: that self-selection bias contributed to lack of medication advantage at the 36-month assessment of the Multimodal Treatment Study of Children With ADHD (MTA) and that overall improvement over time obscured treatment effects in subgroups with different outcome trajectories. METHOD Propensity score analyses, using baseline characteristics and severity of attention-deficit/hyperactivity disorder symptoms at follow-up, established five subgroups (quintiles) based on tendency to take medication at the 36-month assessment. Growth mixture model (GMM) analyses were performed to identify subgroups (classes) with different patterns of outcome over time. RESULTS All five propensity subgroups showed initial advantage of medication that disappeared by the 36-month assessment. GMM analyses identified heterogeneity of trajectories over time and three classes: class 1 (34% of the MTA sample) with initial small improvement followed by gradual improvement that produced significant medication effects; class 2 (52%) with initial large improvement maintained for 3 years and overrepresentation of cases treated with the MTA Medication Algorithm; and class 3 (14%) with initial large improvement followed by deterioration. CONCLUSIONS We failed to confirm the self-selection hypothesis. We found suggestive evidence of residual but not current benefits of assigned medication in class 2 and small current benefits of actual treatment with medication in class 1.

[1]  Robert D Gibbons,et al.  3-year follow-up of the NIMH MTA study. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[2]  C. Gillberg,et al.  Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. , 1997, Archives of general psychiatry.

[3]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[4]  Donald Hedeker,et al.  Longitudinal Data Analysis , 2006 .

[5]  J. Avorn,et al.  Variable selection for propensity score models. , 2006, American journal of epidemiology.

[6]  Elizabeth B. Owens,et al.  Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[7]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[8]  Stephen P. Hinshaw,et al.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. , 1999, Archives of general psychiatry.

[9]  J. Swanson,et al.  Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[10]  J. Severe,et al.  Reliability of the services for children and adolescents-parent interview. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[11]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[12]  G. Weiss,et al.  Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[13]  J. Swanson,et al.  National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. , 2004, Pediatrics.

[14]  J. Swanson,et al.  National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. , 2004, Pediatrics.

[15]  J. Swanson,et al.  The services for children and adolescents-parent interview: development and performance characteristics. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[16]  Robert D. Gibbons,et al.  Estimating the Efficacy of Receiving Treatment in Randomized Clinical Trials with Noncompliance , 2001, Health Services and Outcomes Research Methodology.

[17]  Elizabeth B. Owens,et al.  Which treatment for whom for ADHD? Moderators of treatment response in the MTA. , 2003, Journal of consulting and clinical psychology.